Printer Friendly

ONCOR, INC. RECEIVES FDA MARKETING APPROVAL FOR DNA-BASED DETECTION AND MONITORING OF LEUKEMIA AND LYMPHOMA IN BONE MARROW

 GAITHERSBURG, Md., Jan. 20 /PRNewswire/ -- Oncor, Inc. (NASDAQ: ONCR), announced today that the U.S. Food and Drug Administration (FDA) has approved Oncor's Premarket Approval (PMA) application for a new indication, bone marrow testing, to its previously approved Oncor B/T Blue(TM) Gene Rearrangement Test System. Oncor submitted its PMA Supplement in August, 1992.
 According to Oncor's president and chief operating officer, George R. Evanega, Ph.D., the Oncor DNA-based cancer diagnostic kit will allow physicians to make a primary diagnosis of leukemia or lymphoma directly from bone marrow, the site of origin for most cancers of this type. "This new indication should enable physicians to diagnose and track these conditions sooner and more effectively since these cancers will generally manifest themselves in the bone marrow before expanding into the peripheral blood," Evanega said.
 "This approval reiterates Oncor's commitment to move our products into the clinical environment by working closely with the FDA and our clinical evaluators," said Oncor's chairman and CEO, Stephen Turner. "We are pleased that the FDA moved quickly to approve this supplement in less than six months."
 The Oncor B/T Blue Test System is currently in use in more than 100 laboratories in the United States. The test can be used to analyze the 85,000 new cases of leukemia and lymphoma diagnosed annually in the U.S., and to monitor the 330,000 or more patients who have suffered from leukemia and lymphoma and who are at risk of recurrence.
 Oncor develops, manufactures and markets Human Genome-based test systems for use in the early detection and management of cancer and other genetic diseases.
 -0- 1/20/93
 /CONTACT: Stephen Turner or George R. Evanega, Ph.D., both of Oncor, Inc., 301-963-3500, or fax 301-926-6129/
 (ONCR)


CO: Oncor, Inc. ST: Maryland IN: MTC SU: PDT

TM-LD -- NY002 -- 6676 01/20/93 07:01 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 20, 1993
Words:310
Previous Article:CLINTON ECONOMIC CONFERENCE ON NEW CD-ROM; JOURNAL GRAPHICS AND UNIDISC, IN COOPERATION WITH CNN, ANNOUNCE A NEW SERIES OF MULTIMEDIA CDs
Next Article:KEMPER FINANCIAL SERVICES INTRODUCES KEMPER RETIREMENT FUND, SERIES IV
Topics:


Related Articles
ONCOR INC. ANNOUNCES DEVELOPMENT OF NEW DNA PROBE THAT ALLOWS DIRECT DETECTION OF GENE AMPLIFIED IN BREAST CANCER CELLS
ONCOR, INC. RECEIVES FDA PERMISSION TO EXPORT CANCER DIAGNOSTIC TESTS TO EUROPEAN COUNTRIES AND AUSTRALIA
ONCOR, INC. RECEIVES FDA PERMISSION TO EXPORT CANCER DIAGNOSTIC TESTS TO GERMANY AND DENMARK
FDA ADVISORY PANEL REQUESTS FURTHER DATA ON ONCOR BREAST CANCER TEST
ONCOR, INC. RECEIVES FDA APPROVABLE LETTER FOR HPV TEST
Preclinical Data Indicate Cerus Technology May Improve Bone Marrow Transplant Outcomes.
Cerus Receives FDA Clearance to Proceed With Clinical Trials Of Its System For Allogeneic Bone Marrow Transplantation.
Vysis Further Strengthens Intellectual Property Portfolio of Key Genomics Platforms.
Vysis obtains multiple genomic target detection patent.
Applied Imaging Announces FDA Clearances to Market Genetic Probe Test.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters